---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-25-000020"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T07:52:30.516451+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Edwards Q1 sales $1.41B (+6.2%), TMTT surging 58%, guidance raised

## Summary
- Q1 sales $1.41B (+6.2% reported, +7.9% adjusted); GAAP EPS $0.62, adjusted EPS $0.64.
- TAVR sales $1.05B (+3.8%, +5.4% constant currency); TMTT sales $115M (+58%).
- Gross margin 78.7%; operating margin 27.9% (adj. 29.1%) on favorable mix and delayed expenses.
- 2025 guidance: total sales raised to $5.7-6.1B; TMTT raised to $530-550M; adj. EPS reaffirmed $2.40-2.50.
- Q2 guidance: sales $1.45-1.53B, adj. EPS $0.59-0.65; CE Mark SAPIEN M3, NCD for EVOQUE.

## SEC filing metadata
- accession: 0001099800-25-000020
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000020/0001099800-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000020/ew-20250423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-25-000020
- JSON: https://secwatch.observer/filing/0001099800-25-000020.json
- Plain text: https://secwatch.observer/filing/0001099800-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.